Skip to main content

Animations

MJFF Publications

5711 - 5720 of 8785 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2022
  • 2022
  • 2021
  • 2021
  • Summary Details
    RESTRICTED
    Title: A Ranking-based Weakly Supervised Learning model for telemonitoring of Parkinson’s disease
    Journal Name: IISE Transactions on Healthcare Systems Engineering
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1080/24725579.2022.2091065
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Identification of risk factors for impulse-control disorder symptoms in patients with Parkinson’s disease
    Journal Name: Journal of Physics: Conference Series
    Publisher: IOP Publishing
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1088/1742-6596/1722/1/012099
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Analysis of factors associated with early stage Parkinson’s disease based on daily activities and sleeping behaviour disorder
    Journal Name: Journal of Physics: Conference Series
    Publisher: IOP Publishing
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1088/1742-6596/1722/1/012045
    Citation Count: 1
  • Summary Details
    OPEN
    Title: NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awab214
    Citation Count: 15
  • Summary Details
    RESTRICTED
    Title: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41591-021-01455-x
    Citation Count: 103
  • Summary Details
    RESTRICTED
    Title: Aducanumab: look before leaping
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41591-021-01477-5
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Deep brain stimulation for obsessive–compulsive disorder: a crisis of access
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41591-022-01879-z
    Citation Count: 67
  • Summary Details
    RESTRICTED
    Title: Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
    Journal Name: Nature Structural & Molecular Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41594-022-00837-0
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease
    Journal Name: Nature Aging
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s43587-021-00071-1
    Citation Count: 37
  • Summary Details
    RESTRICTED
    Title: Dysregulated miRNAs mark Parkinson’s disease progression
    Journal Name: Nature Aging
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s43587-021-00046-2
    Citation Count: 1
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.